drugset / Trial / NCT01276054

Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.

NCT01276054

RandomizedParallel-groupOpen-labelSupportive care

Summary

Lymph node biopsy followed by axillary reverse mapping may reduce the incidence and severity of arm lymphedema. This randomized phase II trial is studying how well sentinel and/or axillary lymph node biopsy with or without axillary reverse mapping works in reducing incidence and severity of lymphedema in patients with resectable stage 0-II breast cancer

Timeline

Start
2010-12
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Background Methylene Blue Diagnostic / imaging agent Subcutaneous
Background indocyanine green solution Diagnostic / imaging agent Subcutaneous